GHK-Cu vs MOTS-c: What Separates Them

GHK-Cu and MOTS-c differ starting from their origin: GHK-Cu is a synthetic tripeptide that binds a copper ion and is studied mainly in models of skin, wound healing and connective tissue remodeling, while MOTS-c is a peptide encoded by mitochondrial DNA that is studied in energy metabolism, insulin resistance and exercise response. They do not compete for the same research territory — the confusion usually comes from both compounds showing up in the same research catalogues, not from any overlap in what they do.

What GHK-Cu is and what the literature studies it for

GHK-Cu is the copper-complexed form of the tripeptide glycine-histidine-lysine (Gly-His-Lys), a sequence originally isolated from human plasma that has a natural affinity for copper(II) ions. That binding to copper is not a cosmetic detail: most of the biological activity reported in the literature depends on the peptide being complexed, not free.

Studies indexed on PubMed associate it mainly with:

• Models of connective tissue repair and extracellular matrix activity.
• Research on dermal fibroblasts and collagen expression.
• Wound-healing models in skin.
• Studies on hair follicle remodeling.

It is one of the peptides with the longest publication history within the copper-binding peptide family, and it is also one of the few compounds in PeptoClinic's catalogue where the batch specification is open to direct verification: the laboratory report for this compound (a 50 mg batch) carries an online verification key, though the document itself does not state a purity percentage. You can see the full entry on the GHK-Cu Argentina page.

What MOTS-c is and why it's called a "mitochondrial peptide"

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is different in its biological nature from the ground up: it is not a fragment designed to mimic a hormone, but a 16-amino-acid sequence encoded inside human mitochondrial DNA itself, only discovered in 2015. That difference in origin is the first thing that separates it from GHK-Cu: one comes from a plasma-derived sequence, the other from a region of the mitochondrial genome that for decades had not been mapped as coding.

The published research studies it in a completely different field than GHK-Cu:

• Models of metabolic homeostasis and insulin sensitivity.
• Research on mitochondrial-to-nuclear communication (retrograde mitonuclear signaling).
• Models of adaptive response to metabolic stress, including exercise.
• Studies on AMPK regulation in muscle tissue.

In the laboratory report PeptoClinic has published for this compound — analyzed by Janoshik Analytical on April 13, 2026, a batch with 11.31 mg of content — purity came in at 99.669%. Of the four reports published in the catalogue, that is the lowest figure on any of them, which is exactly why it's worth citing: it's the real floor, not the best case. You can see the detail on the MOTS-c Argentina page.

The difference that matters most: which biological system each one targets

If you had to reduce the difference to a single idea, it would be this: GHK-Cu is studied as an extracellular signaling molecule, tied to tissue matrix and skin; MOTS-c is studied as an intracellular signaling molecule, tied to the mitochondria and energy metabolism. Neither substitutes for the other in any research protocol, because they answer different questions.

That difference also shows up in how the two get grouped inside a research peptide catalogue. GHK-Cu tends to appear near compounds oriented toward tissue and regeneration, like BPC-157, while MOTS-c tends to be grouped with peptides oriented toward metabolic axis and body composition, like CJC-1295 without DAC. That grouping isn't arbitrary — it follows the literature, not the other way around.

The structural difference, in plain terms

GHK-Cu is a tripeptide: three amino acids (glycine, histidine, lysine) bound to a copper atom. It's a small molecule even within the universe of research peptides. MOTS-c is larger, at 16 amino acids, and carries no complexed metal — its biological activity depends on the amino acid sequence itself, not on a bound cofactor.

That difference in size and chemistry isn't just a curiosity. It shapes how each is handled, stored and analyzed in the laboratory, and it's part of why each one has its own specification sheet in the catalogue instead of sharing a generic one.

What documentation ships with each batch

Both compounds arrive as lyophilized powder in a sealed vial, with no cold chain, because in lyophilized form they are stable at room temperature for weeks. The difference between the two is in the analytical report that accompanies the batch:

• The MOTS-c report (task 136923) states 99.669% purity on 11.31 mg of content.
• The GHK-Cu report (task 204977) corresponds to a 50 mg batch and carries an online verification key, but the document does not state a purity figure.

Before comparing any batch from any supplier, it's worth knowing how to read that documentation critically: the page on evaluating peptide quality explains what to look for in a certificate of analysis beyond the big number on the first page.

What the literature does not study, for either compound

Neither GHK-Cu nor MOTS-c is studied, in the available literature, as a treatment for any human condition. What exists are laboratory models — cell lines, animal models, in vitro assays — exploring mechanisms. In neither case is there clinical evidence that would support talk of an established therapeutic use.

The material PeptoClinic supplies is strictly for laboratory research (Research Use Only). It is not approved for human or veterinary use, it is not a drug, a supplement or a cosmetic product, and none of its properties have been evaluated by the FDA, ANMAT or any equivalent authority.

Anyone looking for either of these two compounds with the intent of applying it to a person is asking a question this page does not answer, because it is not the question PeptoClinic is positioned to answer: the catalogue exists for research, and the documentation that ships with each batch — certificate of analysis, batch traceability, dispatch conditions — is built with that purpose in mind.

How each one is quoted

Neither compound has a published price: PeptoClinic operates as a technical consultancy, not a storefront. A researcher describes the specification they need — compound, quantity, batch — and the technical team responds with a written quote, normally within one business day. You can review the full catalogue to see which other compounds are available, or the Argentina shipping page to understand how import documentation is prepared for this material as laboratory reference material.